MENLO PARK, Calif., Nov. 10, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX) will nearly double its national retail footprint for the company's breast health supplement, Violet® iodine, when it will become available in 3,025 GNC store locations in the United States next month.
Violet iodine, a first-of-its-kind breast health supplement for women, relieves the painful symptoms of monthly breast discomfort and dense, fibrous breast tissue. It is currently available for purchase at select CVS Pharmacy locations, the Vitamin Shoppe, Harris Teeter grocery stores, and online at drugstore.com, and walgreens.com.
"GNC is a leading global specialty retailer of health and wellness products and is devoted to helping its customers improve the quality of their lives," said Anja Krammer, president and co-founder of BioPharmX Corporation. "By putting Violet on its shelves, GNC is empowering women to proactively manage their own breast health and allows us to continue our journey in making breast health solutions available to as many women as possible."
Availability of Violet iodine at GNC is expected to begin in mid-December.
For more information on Violet iodine, please visit www.violetdaily.com.
About BioPharmX™ Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the health and wellness markets, including women's health and dermatology. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those section. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding, including with respect to: the success of the commercialization of VI2OLET iodine, the effectiveness of BPX01, the timing with respect to filing an IND and clinical trials for BPX01, the release of key data for BPX01, the release of key data and the successful completion of multi-site IRB studies for BPX03 and the successful completion of the private placement with Korea Investment Partners Overseas Expansion Platform Fund. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
SOURCE BioPharmX Corporation